OBJECTIVES: To determine whether synthetic phosphorylated hexa-acyl disaccharides provide antimicrobial protection in clinically relevant models of bacterial infection. DESIGN: Laboratory study. SETTING: University laboratory. SUBJECTS: BALB/c, C57BL/10J, and C57BL/10ScNJ mice. INTERVENTIONS: Mice were treated with lactated Ringer's (vehicle) solution, monophosphoryl lipid A, or phosphorylated hexa-acyl disaccharides at 48 and 24 hours prior to intraperitoneal Pseudomonas aeruginosa or IV Staphylococcus aureus infection. Leukocyte recruitment, cytokine production, and bacterial clearance were measured 6 hours after P. aeruginosa infection. In the systemic S. aureus infection model, one group of mice was monitored for 14-day survival and another for S. aureus tissue burden at 3 days postinfection. Duration of action for 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide was determined at 3, 10, and 14 days using a model of intraperitoneal P. aeruginosa infection. Effect of 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide on in vivo leukocyte phagocytosis and respiratory burst was examined. Leukocyte recruitment, cytokine production, and bacterial clearance were measured after P. aeruginosa infection in wild-type and toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide or vehicle to assess receptor specificity. MEASUREMENTS AND MAIN RESULTS: During intraperitoneal P. aeruginosa infection, phosphorylated hexa-acyl disaccharides significantly attenuated infection-induced hypothermia, augmented leukocyte recruitment and bacterial clearance, and decreased cytokine production. At 3 days post S. aureus infection, bacterial burden in lungs, spleen, and kidneys was significantly decreased in mice treated with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides, which was associated with improved survival. Leukocyte phagocytosis and respiratory burst functions were enhanced after treatment with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides. A time course study showed that monophosphoryl lipid A- and 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide-mediated protection against P. aeruginosa lasts for up to 10 days. Partial loss of augmented innate antimicrobial responses was observed in toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide. CONCLUSIONS: Phosphorylated hexa-acyl disaccharides significantly augment resistance against clinically relevant Gram-negative and Gram-positive infections via enhanced leukocyte recruitment, phagocytosis, and respiratory burst functions of innate leukocytes. Improved antimicrobial protection persists for up to 10 days and is partially mediated through toll-like receptor 4.
OBJECTIVES: To determine whether synthetic phosphorylated hexa-acyl disaccharides provide antimicrobial protection in clinically relevant models of bacterial infection. DESIGN: Laboratory study. SETTING: University laboratory. SUBJECTS: BALB/c, C57BL/10J, and C57BL/10ScNJ mice. INTERVENTIONS:Mice were treated with lactated Ringer's (vehicle) solution, monophosphoryl lipid A, or phosphorylated hexa-acyl disaccharides at 48 and 24 hours prior to intraperitoneal Pseudomonas aeruginosa or IV Staphylococcus aureus infection. Leukocyte recruitment, cytokine production, and bacterial clearance were measured 6 hours after P. aeruginosa infection. In the systemic S. aureus infection model, one group of mice was monitored for 14-day survival and another for S. aureus tissue burden at 3 days postinfection. Duration of action for 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide was determined at 3, 10, and 14 days using a model of intraperitoneal P. aeruginosa infection. Effect of 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide on in vivo leukocyte phagocytosis and respiratory burst was examined. Leukocyte recruitment, cytokine production, and bacterial clearance were measured after P. aeruginosa infection in wild-type and toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide or vehicle to assess receptor specificity. MEASUREMENTS AND MAIN RESULTS: During intraperitoneal P. aeruginosa infection, phosphorylated hexa-acyl disaccharides significantly attenuated infection-induced hypothermia, augmented leukocyte recruitment and bacterial clearance, and decreased cytokine production. At 3 days post S. aureus infection, bacterial burden in lungs, spleen, and kidneys was significantly decreased in mice treated with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides, which was associated with improved survival. Leukocyte phagocytosis and respiratory burst functions were enhanced after treatment with monophosphoryl lipid A or phosphorylated hexa-acyl disaccharides. A time course study showed that monophosphoryl lipid A- and 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide-mediated protection against P. aeruginosa lasts for up to 10 days. Partial loss of augmented innate antimicrobial responses was observed in toll-like receptor 4 knockout mice treated with 3-deacyl 6-Acyl phosphorylated hexa-acyl disaccharide. CONCLUSIONS: Phosphorylated hexa-acyl disaccharides significantly augment resistance against clinically relevant Gram-negative and Gram-positive infections via enhanced leukocyte recruitment, phagocytosis, and respiratory burst functions of innate leukocytes. Improved antimicrobial protection persists for up to 10 days and is partially mediated through toll-like receptor 4.
Authors: Jonathan L Schmid-Burgk; Moritz M Gaidt; Tobias Schmidt; Thomas S Ebert; Eva Bartok; Veit Hornung Journal: Eur J Immunol Date: 2015-08-06 Impact factor: 5.532
Authors: Nobuhiko Kayagaki; Michael T Wong; Irma B Stowe; Sree Ranjani Ramani; Lino C Gonzalez; Sachiko Akashi-Takamura; Kensuke Miyake; Juan Zhang; Wyne P Lee; Artur Muszyński; Lennart S Forsberg; Russell W Carlson; Vishva M Dixit Journal: Science Date: 2013-07-25 Impact factor: 47.728
Authors: Benjamin A Fensterheim; Jamey D Young; Liming Luan; Ruby R Kleinbard; Cody L Stothers; Naeem K Patil; Allison G McAtee-Pereira; Yin Guo; Irina Trenary; Antonio Hernandez; Jessica B Fults; David L Williams; Edward R Sherwood; Julia K Bohannon Journal: J Immunol Date: 2018-04-23 Impact factor: 5.422
Authors: Lori F Gentile; Alex G Cuenca; Philip A Efron; Darwin Ang; Azra Bihorac; Bruce A McKinley; Lyle L Moldawer; Frederick A Moore Journal: J Trauma Acute Care Surg Date: 2012-06 Impact factor: 3.313
Authors: Naeem K Patil; Julia K Bohannon; Liming Luan; Yin Guo; Benjamin Fensterheim; Antonio Hernandez; Jingbin Wang; Edward R Sherwood Journal: Shock Date: 2017-01 Impact factor: 3.454
Authors: Julia K Bohannon; Liming Luan; Antonio Hernandez; Aqeela Afzal; Yin Guo; Naeem K Patil; Benjamin Fensterheim; Edward R Sherwood Journal: J Leukoc Biol Date: 2015-11-04 Impact factor: 4.962
Authors: Antonio Hernandez; Naeem K Patil; Cody L Stothers; Liming Luan; Margaret A McBride; Allison M Owen; Katherine R Burelbach; David L Williams; Edward R Sherwood; Julia K Bohannon Journal: Pharmacol Res Date: 2019-11-02 Impact factor: 7.658
Authors: Cody L Stothers; Katherine R Burelbach; Allison M Owen; Naeem K Patil; Margaret A McBride; Julia K Bohannon; Liming Luan; Antonio Hernandez; Tazeen K Patil; David L Williams; Edward R Sherwood Journal: J Immunol Date: 2021-11-05 Impact factor: 5.426
Authors: Robert E Haupt; Erin M Harberts; Robert J Kitz; Shirin Strohmeier; Florian Krammer; Robert K Ernst; Matthew B Frieman Journal: Vaccine Date: 2021-08-03 Impact factor: 4.169
Authors: Margaret A McBride; Allison M Owen; Cody L Stothers; Antonio Hernandez; Liming Luan; Katherine R Burelbach; Tazeen K Patil; Julia K Bohannon; Edward R Sherwood; Naeem K Patil Journal: Front Immunol Date: 2020-05-29 Impact factor: 7.561
Authors: Margaret A McBride; Tazeen K Patil; Julia K Bohannon; Antonio Hernandez; Edward R Sherwood; Naeem K Patil Journal: Front Immunol Date: 2021-02-03 Impact factor: 7.561
Authors: Allison M Owen; Jessica B Fults; Naeem K Patil; Antonio Hernandez; Julia K Bohannon Journal: Front Immunol Date: 2021-02-18 Impact factor: 7.561